More than one third of cardiovascular-related randomized controlled clinical trials funded by the National Heart, Lung, and Blood Institute (NHLBI) were published within 30 months of their completion, according to an analysis published Nov. 14 in the New England Journal of Medicine.

When it comes to value, warfarin may be the best option for reducing the risk of stroke and thromboembolism in patients with atrial fibrillation.

In response to rising national health care costs, the Indiana University School of Medicine and Indiana Clinical and Translational Sciences Institute have launched a new center to increase efficacy and reduce costs at four major health care providers across Indiana.

Demand for cardiology services will grow by 20 percent in the next dozen years, according to a recent projection. Maybe.

Demand for cardiology services will grow by 20 percent by 2025, according to a projection published in the November issue of Health Affairs, and radiology will experience an 18 percent bump.

Concerns that conversion of hospitals from not-for-profit to for-profit status compromises patient outcomes appear to be unfounded.

In an analysis of a subset of North American patients in the EINSTEIN-PE trial, Brahim Bookhart, director of Health Economics and Outcomes Research at Janssen Research & Development, and colleagues reported that patients who received rivaroxaban (Xarelto) had a shorter length of stay. That translated into savings of $2,040 per patient.

Implementing a comprehensive cardiac rehabilitation (CR) program may ultimately cut costs by reducing the number of hospital readmissions and lowering mortality from cardiovascular disease, according to study results presented Oct. 17 at the Canadian Cardiovascular Congress in Montreal.